Literature DB >> 1561085

The 4-nitroquinoline 1-oxide mutational spectrum in single stranded DNA is characterized by guanine to pyrimidine transversions.

G Fronza1, P Campomenosi, R Iannone, A Abbondandolo.   

Abstract

4-Nitroquinoline-1-oxide is a potent mutagen and carcinogen which induces two main guanine adducts at positions C8 and N2. In ds or ss damaged DNA the ratio C8/N2 adducts is 1:2 and 8-10:1, respectively. In bacteria and yeast 4NQO has been shown to be a base substitution mutagen acting at G residues inducing mainly G to A transitions. We determined the mutational spectrum induced by the 4NQO metabolite, acetoxy-4-aminoquinoline 1-oxide, in the M13lacZ'/E. coli lacZ delta M15 alpha complementation assay using ssDNA. Among 68 Ac-4HAQO induced mutants, G to Pyr transversion was the most frequent base substitution observed. By comparison with dsDNA based systems, our data suggest that dGuo-C8-AQO induces G to Pyr transversions. A mechanism to explain how this lesion may induce transversions is proposed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1561085      PMCID: PMC312171          DOI: 10.1093/nar/20.6.1283

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  40 in total

1.  Carcinogens leave fingerprints.

Authors:  B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

2.  Mutagenicity of N2 guanylarylation is SOS functions dependent and reminiscent of the high mutagenic property of 4NQO.

Authors:  S Galiègue-Zouitina; P Daubersies; M H Loucheux-Lefebvre; B Bailleul
Journal:  Carcinogenesis       Date:  1989-10       Impact factor: 4.944

3.  Site-specific mutagenesis using a gapped duplex vector: a study of translesion synthesis past 8-oxodeoxyguanosine in E. coli.

Authors:  M Moriya; C Ou; V Bodepudi; F Johnson; M Takeshita; A P Grollman
Journal:  Mutat Res       Date:  1991-05       Impact factor: 2.433

4.  Genetic studies of the lac repressor. IV. Mutagenic specificity in the lacI gene of Escherichia coli.

Authors:  C Coulondre; J H Miller
Journal:  J Mol Biol       Date:  1977-12-15       Impact factor: 5.469

5.  Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome.

Authors:  M L Wood; M Dizdaroglu; E Gajewski; J M Essigmann
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

6.  Sequence analysis of ultraviolet-induced mutations in M13lacZ hybrid phage DNA.

Authors:  J E LeClerc; N L Istock; B R Saran; R Allen
Journal:  J Mol Biol       Date:  1984-12-05       Impact factor: 5.469

7.  Genetic effects of thymine glycol: site-specific mutagenesis and molecular modeling studies.

Authors:  A K Basu; E L Loechler; S A Leadon; J M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Adducts from the reaction of O,O'-diacetyl or O-acetyl derivatives of the carcinogen 4-hydroxyaminoquinoline 1-oxide with purine nucleosides.

Authors:  B Bailleul; S Galiègue; M H Loucheux-Lefebvre
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  NMR structural studies of the ionizing radiation adduct 7-hydro-8-oxodeoxyguanosine (8-oxo-7H-dG) opposite deoxyadenosine in a DNA duplex. 8-Oxo-7H-dG(syn).dA(anti) alignment at lesion site.

Authors:  M Kouchakdjian; V Bodepudi; S Shibutani; M Eisenberg; F Johnson; A P Grollman; D J Patel
Journal:  Biochemistry       Date:  1991-02-05       Impact factor: 3.162

Review 10.  Molecular basis of 4-nitroquinoline 1-oxide carcinogenesis.

Authors:  B Bailleul; P Daubersies; S Galiègue-Zouitina; M H Loucheux-Lefebvre
Journal:  Jpn J Cancer Res       Date:  1989-08
View more
  7 in total

1.  4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.

Authors:  Li-E Wang; Chunying Li; Ping Xiong; Jeffrey E Gershenwald; Victor G Prieto; Madeleine Duvic; Jeffrey E Lee; Elizabeth A Grimm; Tao C Hsu; Qingyi Wei
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

2.  The inactive form of glycogen synthase kinase-3β is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice.

Authors:  Daniella Fernandes Mendonça; Roger Chammas; Fu-Tong Liu; Suely Nonogaki; Sergio Vitorino Cardoso; Adriano Mota Loyola; Paulo Rogério de Faria
Journal:  Int J Clin Exp Pathol       Date:  2012-07-17

Review 3.  Antimutagenic compounds and their possible mechanisms of action.

Authors:  Karolina Słoczyńska; Beata Powroźnik; Elżbieta Pękala; Anna M Waszkielewicz
Journal:  J Appl Genet       Date:  2014-03-11       Impact factor: 3.240

4.  In Vitro Biotransformation, Safety, and Chemopreventive Action of Novel 8-Methoxy-Purine-2,6-Dione Derivatives.

Authors:  Małgorzata Anna Marć; Enrique Domínguez-Álvarez; Karolina Słoczyńska; Paweł Żmudzki; Grażyna Chłoń-Rzepa; Elżbieta Pękala
Journal:  Appl Biochem Biotechnol       Date:  2017-06-17       Impact factor: 2.926

5.  Physicochemical Characterization, Microbiological Quality and Safety, and Pharmacological Potential of Hancornia speciosa Gomes.

Authors:  Uilson Pereira Dos Santos; Georgina S Tolentino; Jorge Sá Morais; Kely de Picoli Souza; Leticia M Estevinho; Edson Lucas Dos Santos
Journal:  Oxid Med Cell Longev       Date:  2018-06-28       Impact factor: 6.543

6.  Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity.

Authors:  Małgorzata Anna Marć; Enrique Domínguez-Álvarez; Gniewomir Latacz; Agata Doroz-Płonka; Carmen Sanmartín; Gabriella Spengler; Jadwiga Handzlik
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

Review 7.  Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma.

Authors:  Qiang Li; Heng Dong; Guangwen Yang; Yuxian Song; Yongbin Mou; Yanhong Ni
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.